DOI: 10.5281/zenodo.15721137
title: Integrated omics analysis uncovers the impact of antiseizure medications on developmental pathways and the protective role of folic acid

description: SUPPLEMENTARY FILES

Supplementary File S1- Impact of antiseizure medications on cell viability.

Supplementary File S2- Therapeutic and toxic serum concentrations of antiseizure medications used in this study.

Supplementary File S3- List of primers used in this study: Primer sequence of genes used in the expression analysis.

Supplementary File S4- Effect of antiseizure drugs on the mRNA expression of DNA methyltransferases and DNA demethylases in HEK293.

Supplementary File S5– Effect of antiseizure drugs on the mRNA expression of One–carbon Metabolism genes in HEK293.

Supplementary File S6- Differentially methylated sites associated with Carbamazepine treatment: Listed are all the significant differentially methylated probes in AC vs. CBZ comparison.

Supplementary File S7- Differentially methylated sites associated with Phenytoin treatment: Listed are all the significant differentially methylated probes in AC vs. PHT comparison.

Supplementary File S8- Differentially methylated sites associated with Valproic acid treatment: Listed are all the significant differentially methylated probes in AC vs. VPA comparison.

Supplementary File S9- Differentially methylated sites associated with CBZ + Folic acid treatment: Listed are all the significant differentially methylated probes in AC vs. CF comparison.

Supplementary File S10- Differentially methylated sites associated with PHT + Folic acid treatment: Listed are all the significant differentially methylated probes in AC vs. PF comparison.

Supplementary File S11-Differentially methylated sites associated with VPA + Folic acid treatment: Listed are all the significant differentially methylated probes in AC vs. VF comparison.

Supplementary File S12- Differentially methylated sites associated with Folic acid treatment: Listed are all the significant differentially methylated probes in AC vs. FA comparison.

Supplementary File S13 -Summary of data filtering and protein identification across different treatment conditions.

Supplementary File S14- Differentially expressed proteins in Assay Control vs Carbamazepine treated group: Listed are all the significant differentially expressed proteins (FDR<0.05) in AC vs. CBZ comparison.                                                                        

Supplementary File S15- Differentially expressed proteins in Assay Control vs Phenytoin treated group: Listed are all the significant differentially expressed proteins (FDR<0.05) in AC vs. PHT comparison                                                                                          

Supplementary File S16- Differentially expressed proteins in Assay Control vs valproic acid treated group: Listed are all the significant differentially expressed proteins (FDR<0.05) in AC vs. VPA comparison                                                                                          

Supplementary File S17-      Differentially expressed proteins in Assay Control vs Carbamazepine + Folic acid (CF) treated group: Listed are all the significant differentially expressed proteins (FDR<0.05) in AC vs. CF comparison.                                   

Supplementary File S18-      Differentially expressed proteins in Assay Control vs phenytoin + Folic acid (PF) treated group: Listed are all the significant differentially expressed proteins (FDR<0.05) in AC vs. PF comparison.

Supplementary File S19- Differentially expressed proteins in Assay Control vs Valproic acid + Folic acid (VF) treated group: Listed are all the significant differentially expressed proteins (FDR<0.05) in AC vs. VF comparison.                 

Supplementary File S20- Differentially expressed proteins in Assay Control vs Folic acid (FA) treated group: Listed are all the significant differentially expressed proteins (FDR<0.05) in AC vs. FA comparison                                                                                                

Supplementary File S21-Differentially expressed proteins in Carbamazepine vs Carbamazepine + Folic acid (CF) treated group: Listed are all the significant differentially expressed proteins (FDR<0.05) in C vs. CF comparison                                                      

Supplementary File S22- Differentially expressed proteins in phenytoin vs phenytoin + Folic acid (PF) treated group: Listed are all the significant differentially expressed proteins (FDR<0.05) in P vs. PF comparison      

Supplementary File S23-Differentially expressed proteins in valproic acid vs valproic acid + Folic acid (VF) treated group: Listed are all the significant differentially expressed proteins (FDR<0.05) in V vs. VF comparison                                                                                          

Supplementary File S24 -Functional Enrichment analysis of differentially methylated probes associated with Carbamazepine treatment: Listed are all the significant Gene Ontology terms (FDR<0.05).

Supplementary File S25 -Functional Enrichment analysis of differentially methylated probes associated with Phenytoin treatment: Listed are all the significant Gene Ontology terms (FDR<0.05).

Supplementary File S26 - Functional Enrichment analysis of differentially methylated probes associated with Valproic acid treatment: Listed are all the significant Gene Ontology terms (FDR<0.05).

Supplementary File S27- Functional Enrichment analysis of upregulated proteins in drug alone treatment groups: Listed are all the significant Gene Ontology terms (FDR<0.05) 

Supplementary File S28- Functional Enrichment analysis of downregulated proteins in drug alone treatment groups: Listed are all the significant Gene Ontology terms (FDR<0.05)